Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases

Clinical trial NCT06828042 · RECRUITING

Trial details

NCT number: NCT06828042
Sponsor: Peking University Third Hospital
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Systemic Lupus Erthematosus Systemic Sclerosis (SSc)Sjogren Syndrome ANCA Associated Vasculitis (AAV)Inflammatory Myopathies Antiphospholipid Syndrome

Start date: 2025-07-01
Primary completion: 2027-12-31
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.